A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04204616
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
500
Enrollment
INDUSTRY
Sponsor class
Conditions
Prurigo Nodularis
Interventions
DRUG:
Nemolizumab
Sponsor
Galderma R&D